I had to add a few more shares. Many weeks ago, I postulated that the orphan indication would be catastrophic antiphospholipid antibody syndrome. I figured they had some info on complements and thrombosis that would lead them there. Turns out I was wrong...but not by much. This news confirms that the blood bank analysis has turned up important info on complement deactivation. PNH is just the start. Take some time to read about C3 nephritic factor and glomerulonephritis. Read up on atypical HUS. These are all conditions I have had the chance to treat. They are all important conditions with high morbidity and potentially high mortality. There are many more possibilities. RVX is turning itself into a big Pharma. This will take a while but they are laying there cards on the table. With financial backing in place, the road could be a very long and profitable one with a Nasdaq uplisting and a much higher SP. Bfw